Niagen Bioscience (NAGE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 24, 2026, at 3:00 pm PT in Los Angeles, CA.
Shareholders will vote on director elections, auditor ratification, and executive compensation.
Proxy materials and annual report are available online, with options for electronic or paper delivery.
Voting matters and shareholder proposals
Election of eight directors is up for shareholder vote, with board recommending approval.
Ratification of Crowe LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation as recommended by the Compensation Committee and approved by the board.
Board of directors and corporate governance
Board recommends voting for all eight nominated directors.
Director nominees include Frank Jaksch, Jr., Robert Fried, Steven Rubin, Wendy Yu, Gary Ng, Kristin Patrick, Ann Cohen, and Hamed Shahbazi.
Latest events from Niagen Bioscience
- NB4168 advances NAD science into pharmaceuticals, targeting rare diseases with strong safety data.NAGE
Fireside chat15 Jul 2026 - Advancing NB4168 for rare genetic diseases with strong clinical data and premium market potential.NAGE
Corporate presentation15 Jul 2026 - Record revenue, profitability, and cash flow set the stage for double-digit growth in 2025.NAGE
Q4 20249 Jul 2026 - Patented NAD+ products, strong clinical data, and expanding verticals drive robust growth.NAGE
Corporate presentation8 Jul 2026 - Registering up to $125M in securities, including $50M at-the-market, to fund growth and operations.NAGE
Registration filing29 Jun 2026 - Strong growth in NAD-based health products, injectables, and skincare, with expanding partnerships.NAGE
16th Annual East Coast IDEAS Conference12 Jun 2026 - Q1 2026 net sales rose 3% to $31.5M, net income $6.3M, $4.8M segment sale gain, $66.5M cash.NAGE
Q1 20266 May 2026 - Board recommends approval of all proposals, emphasizing governance and performance-linked pay.NAGE
Proxy filing29 Apr 2026 - Double-digit growth, strong margins, and clinical validation drive expansion in NAD+ wellness.NAGE
Corporate presentation4 Mar 2026